Annexin Pharmaceuticals AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was SEK 8.57 million compared to SEK 11.51 million a year ago. Basic loss per share from continuing operations was SEK 0.05 compared to SEK 0.08 a year ago.
For the six months, net loss was SEK 18.67 million compared to SEK 20.96 million a year ago. Basic loss per share from continuing operations was SEK 0.12 compared to SEK 0.15 a year ago.